ArticleBMC cancer2018
Trends in molecular subtypes of breast cancer: description of incidence rates between 2007 and 2012 from three French registries.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025.Current oncology (Toronto, Ont.) · 2026Guideline
- Continental differences in the association between excess body weight and prognosis in triple-negative breast cancer: a meta-analysis.Breast cancer research and treatment · 2025Pooled it
- Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.The oncologist · 2024Trial
- Real-World Clinical Experience of First-Line Ribociclib Combined with an Aromatase Inhibitor in Metastatic Breast Cancer.Cancers · 2026Article
- Article
- Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer.Therapeutic advances in medical oncology · 2026Article
- A Life course approach to investigate breast cancer and migration in the greater Paris area: the SENOVIE study protocol.BMJ open · 2025Observational
- Article
- Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary.Discover oncology · 2024Article
- Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer.Clinical pharmacokinetics · 2024Review
- Molecular subtypes as a prognostic breast cancer factor in women users of the São Paulo public health system, Brazil.Revista brasileira de epidemiologia = Brazilian journal of epidemiology · 2023Article
- Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes.Cancers · 2022Article
- Pathological Significance of GLUT-1 Expression in Breast Cancer Cells in Diabetic and Obese Patients: The French Guiana Study.Cancers · 2022Article
- Rule-Based Information Extraction from Free-Text Pathology Reports Reveals Trends in South African Female Breast Cancer Molecular Subtypes and Ki67 Expression.BioMed research international · 2022Article
- A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.Current oncology (Toronto, Ont.) · 2020Article
- Biomarker predictors for immunotherapy benefit in breast: beyond PD-L1.Current breast cancer reports · 2019Article
- Clinical and epidemiologic factors associated with breast cancer and its subtypes among Northeast Chinese women.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe incidence and incidence trends of breast cancer according to molecular subtype are unknown at a population level in France. The registry data enables this study and may give this information, that is crucial to describe and understand breast cancer epidemiology.
methodsWe estimated the incidence rates of breast cancer for each molecular subtype using data from three cancer registries in France for the period from 2007 to 2012. Molecular subtypes were defined with immunohistochemical data. Poisson models were estimated to modelize the course of breast cancer incidence and to test the trends.
resultsThe study included 12,040 patients diagnosed between 2007 and 2012 in the three administrative areas covered by the registries. There was no significant trends in the proportion of each molecular subtype year by year. The age distribution of incident cases was different depending on the molecular subtypes (p < 0.001). The course of incidence between 2007 and 2012 was also different depending on molecular subtype according to the multivariate Poisson model (p < 0.001).
conclusionThe description of incident cases of breast cancer according to molecular subtype at a population level showed differences in trends. The trends in incidence differed according to molecular subtype, and this should improve our understanding of overall changes in incidence. This analysis is important to plan screening and treatment resources at a population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.